|1.||Ross, Ruth A: 3 articles (02/2012 - 06/2010)|
|2.||Brown, Andrew J: 2 articles (12/2013 - 04/2011)|
|3.||Belinson, J: 2 articles (10/2001 - 03/2001)|
|4.||Xu, Y: 2 articles (10/2001 - 03/2001)|
|5.||Becker, Lance B: 1 article (10/2015)|
|6.||Kim, Junhwan: 1 article (10/2015)|
|7.||Lampe, Joshua W: 1 article (10/2015)|
|8.||Yin, Tai: 1 article (10/2015)|
|9.||Shinozaki, Koichiro: 1 article (10/2015)|
|10.||Trauger, Sunia A: 1 article (08/2015)|
12/01/2013 - "Lysophosphatidylinositol (LPI) is emerging as a key modulator of cell proliferation, migration, and function, and holds important pathophysiological implications due to its high levels in diseased tissues, such as in cancer. "
05/01/2011 - "Evidence points to a role of L-α-lysophosphatidylinositol (LPI) in cancer. "
06/01/2010 - "Increased circulating levels of L-alpha-lysophosphatidylinositol (LPI) are associated with cancer and LPI is a potent, ligand for the G-protein-coupled receptor GPR55. "
12/15/1987 - "Accumulation of lysophosphatidylinositol in RAW 264.7 macrophage tumor cells stimulated by lipid A precursors."
08/01/2015 - "Emerging evidence indicates the involvement of GPR55 and its proposed endogenous ligand, lysophosphatidylinositol (LPI), in nociception, yet their role in central pain processing has not been explored. "
04/01/2011 - "GPR55 is a G protein-coupled receptor activated by L-α-lysophosphatidylinositol and suggested to have roles in pain signaling, bone morphogenesis, and possibly in vascular endothelial cells. "
|3.||Ovarian Neoplasms (Ovarian Cancer)
10/01/2001 - "Fatty acid composition of lysophosphatidic acid and lysophosphatidylinositol in plasma from patients with ovarian cancer and other gynecological diseases."
03/01/2001 - "Importantly, the following lysophospholipid species are significantly increased in ascites from patients with ovarian cancer, compared to patients with nonmalignant diseases (e.g., liver failure): LPA (including acyl-, alkyl-, and alkenyl-LPA species), lysophosphatidylinositol, and sphingosylphosphorylcholine. "
07/01/2002 - "This work also provides evidence that a pretreatment with lysophosphatidylcholine or lysophosphatidylinositol (200 nmol/kg) injected as long as 3 days before a severe 6-minute ischemia provided a potent tolerance against neurodegeneration. "
07/01/2002 - "The intravenous injection of lysophosphatidylcholine or lysophosphatidylinositol at a concentration of 200 nmol/kg induced a survival of CA1 pyramidal neurons as high as approximately 95%, even when the treatment was started 30 minutes after 15-minute global ischemia. "
07/01/2002 - "Here we show that certain LPLs, particularly lysophosphatidylcholine and lysophosphatidylinositol, prevent neuronal death both in an in vivo model of transient global ischemia and in an in vitro model of excitotoxicity using primary cultures of cerebellar granule cells exposed to high extracellular concentrations of glutamate (20-40 micromol/L). "
10/01/2015 - "However, a significant increase in lysophosphatidylcholine and lysophosphatidylethanolamine found only in the brain with more damage suggests that impaired phospholipid metabolism may be correlated with the severity of ischemia in CA. In addition, the unique response of lysophosphatidylinositol suggests that phosphatidylinositol metabolism is highly sensitive to cellular conditions altered by ischemia and resuscitation. "
|5.||Breast Neoplasms (Breast Cancer)
06/01/2010 - "A role for L-alpha-lysophosphatidylinositol and GPR55 in the modulation of migration, orientation and polarization of human breast cancer cells."
01/01/2007 - "Using liquid chromatography mass spectrometry (LC/MS/MS), we quantified the amount of lysophosphatidic acid (16:0, 18:0, 18:1, 18:2, and 20:4), lysophosphatidylinositol (18:0), lysophosphatidylserine (18:1), lysophosphatidylcholine (16:0, 18:0, 18:1, 18:2, and 20:4), sphingosine-1-phosphate, and sphingosylphosphorylcholine species from human female plasma samples with malignant, benign, or no breast tumor present. "
|2.||GTP-Binding Proteins (G-Protein)
|3.||lysophosphatidic acid (MOPA)
|5.||Phospholipases A2 (Phospholipase A2)
|7.||Glutamic Acid (Glutamate)